Bio­gen leaps in­to a show­down be­tween Roche and Re­gen­eron, bet­ting on a po­ten­tial new fran­chise play­er

4 years ago
Pharma
FDA+

Mar­ket­ingRx Q&A: Evofem CEO Saun­dra Pel­leti­er on frank con­ver­sa­tions and dis­rupt­ing the con­tra­cep­tion mar­ket

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Ho­log­ic goes to the Su­per Bowl with Mary J. Blige; Hori­zon bows Graves’ dis­ease TV ad

4 years ago
Pharma
Marketing

How UCB beat 2 oth­er bid­ders to land $1.9B buy­out of Zo­genix and its epilep­sy drug

4 years ago
Deals

Mar­tin Shkre­li-as­so­ci­at­ed com­pa­nies set­tle an­ti-com­pet­i­tive law­suit with in­sur­er for $28M

4 years ago
People

Af­ter land­ing funds from Roy­al­ty, Cy­to­ki­net­ics an­nounces afi­camten PhII re­sults; Pol­ish CRO Selvi­ta re­struc­tures in ...

4 years ago
News Briefing

Re­cent­ly stung by AAV, Sarep­ta dives a lit­tle deep­er in­to non-vi­ral de­liv­ery with newest li­cens­ing pact

4 years ago
Deals
Cell/Gene Tx

FDA ex­pands la­bel for Vi­iV's Cabe­nu­va to cov­er bi-month­ly ad­min­is­tra­tion HIV treat­ment

4 years ago
Pharma

Weight loss spin­out Gele­sis ditch­es pro­mo­tion­al staff af­ter SPAC fail — re­port

4 years ago
Pharma
Marketing

Covid-19 roundup: Vac­cine for the youngest kids may be com­ing soon; Mod­er­na wins PRV with full ap­proval

4 years ago
Coronavirus

Trou­bled Alzheimer's play­er Cor­texyme says good­bye to found­ing team as in­de­pen­dent in­vestor takes chair­man­ship

4 years ago
People

Or­p­hazyme CEO de­parts for Leo Phar­ma as both com­pa­nies face ma­jor re­struc­tur­ings

4 years ago
R&D

Af­ter sput­ter­ing on the launch pad, No­vavax fi­nal­ly gets its EUA ap­pli­ca­tion in. Does it mat­ter?

4 years ago
FDA+
Coronavirus

DARPA deputy re­turns home to the UK to lead a new $1B gov­ern­ment re­search agency

4 years ago
People

Ho­log­ic plans Su­per Bowl ad with Mary J. Blige to show women ‘Re­al Love’ means health check­ups

4 years ago
Pharma
Marketing

Take­da spins PhII rare dis­ease pro­grams in­to new start­up — send­ing 2 ex­ecs and some cash to get things go­ing

4 years ago
Startups

Biotech's very bad start to the year con­tin­ues as mi­cro­cap gene ther­a­py play­er Sio ditch­es CEO, lead part­ner­ship

4 years ago
People
R&D

As­traZeneca adds chron­ic kid­ney dis­ease TV ad to Farx­i­ga port­fo­lio

4 years ago
Pharma
Marketing

The big shake­up at a bad­ly rat­tled Bio­gen con­tin­ues as 2 long­time board mem­bers hit the ex­its

4 years ago
R&D

In pledg­ing to vote for Rob Califf, Eliz­a­beth War­ren takes a swing at the FDA-in­dus­try re­volv­ing door

4 years ago
Pharma
FDA+

Mark Cuban's new cost-plus-15% gener­ic drug com­pa­ny is re­al­ly a com­pound­ing phar­ma­cy

4 years ago
Pharma
Manufacturing

The FDA ap­proves Mod­er­na's rev­o­lu­tion­ary new Covid-19 vac­cine. What took so long?

4 years ago
Bioregnum
Pharma

Trou­bled can­cer cen­ter in Con­necti­cut hand­ed Form 483 by FDA, again

4 years ago
Manufacturing

Which FDA guid­ance doc­u­ments are com­ing for drug­mak­ers in 2022? Agency un­veils new lists

4 years ago
Pharma
FDA+
First page Previous page 582583584585586587588 Next page Last page
A service from the Financial Times